LIFESTANCE HEALTH GROUP, INC. Financials LifeStance Health Group, Inc.
Equities
LFST
US53228F1012
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.86 USD | -3.65% |
|
+3.00% | -12.39% |
| May. 09 | Transcript : LifeStance Health Group, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| May. 09 | LifeStance Health Q1 Loss Narrows as Revenue Increases; 2024 Revenue Outlook Reiterated | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,562 | 1,857 | 2,964 | 2,622 | - | - |
| Enterprise Value (EV) 1 | 3,585 | 1,974 | 3,166 | 2,759 | 2,737 | 2,615 |
| P/E ratio | -9.07 x | -8.1 x | -15.4 x | -28.5 x | -31.8 x | -49.7 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 5.34 x | 2.16 x | 2.81 x | 2.15 x | 1.9 x | 1.68 x |
| EV / Revenue | 5.37 x | 2.3 x | 3 x | 2.27 x | 1.99 x | 1.68 x |
| EV / EBITDA | 72.9 x | 37.5 x | 53.6 x | 30.8 x | 22.4 x | 16.4 x |
| EV / FCF | -42.1 x | -74.6 x | -55.2 x | 261 x | 70.2 x | 45.9 x |
| FCF Yield | -2.37% | -1.34% | -1.81% | 0.38% | 1.43% | 2.18% |
| Price to Book | 2.31 x | 1.22 x | 2.08 x | 1.88 x | 1.9 x | 1.89 x |
| Nbr of stocks (in thousands) | 374,149 | 375,986 | 378,607 | 382,288 | - | - |
| Reference price 2 | 9.520 | 4.940 | 7.830 | 6.860 | 6.860 | 6.860 |
| Announcement Date | 3/10/22 | 3/8/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 377.2 | 667.5 | 859.5 | 1,056 | 1,218 | 1,377 | 1,557 |
| EBITDA 1 | - | 49.15 | 52.67 | 59.04 | 89.65 | 122 | 159.4 |
| EBIT 1 | - | -286.4 | -210.2 | -189.1 | -79.1 | -66.9 | -36.9 |
| Operating Margin | - | -42.9% | -24.45% | -17.92% | -6.5% | -4.86% | -2.37% |
| Earnings before Tax (EBT) 1 | - | -333.1 | -232.7 | -206.6 | -102.3 | -85.71 | -61.04 |
| Net income 1 | -311.3 | -343.9 | -215.6 | -186.3 | -89.93 | -76.33 | -48.03 |
| Net margin | -82.53% | -51.53% | -25.08% | -17.64% | -7.39% | -5.54% | -3.09% |
| EPS 2 | - | -1.050 | -0.6100 | -0.5100 | -0.2407 | -0.2157 | -0.1379 |
| Free Cash Flow 1 | - | -85.07 | -26.47 | -57.4 | 10.57 | 39 | 57 |
| FCF margin | - | -12.74% | -3.08% | -5.44% | 0.87% | 2.83% | 3.66% |
| FCF Conversion (EBITDA) | - | - | - | - | 11.8% | 31.95% | 35.76% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 4/12/21 | 3/10/22 | 3/8/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 190.1 | 203.1 | 209.5 | 217.6 | 229.4 | 252.6 | 259.6 | 262.9 | 280.6 | 300.4 | 306 | 302.1 | 312 | 330 | 336.4 |
| EBITDA 1 | 11.4 | 12.48 | 14.63 | 15.38 | 10.18 | 10.1 | 14.06 | 14.58 | 20.29 | 27.65 | 22.38 | 21.65 | 23.11 | 26.58 | 29.49 |
| EBIT 1 | -113.8 | -64.85 | -60.47 | -38.84 | -46.01 | -34.09 | -48.41 | -74.36 | -32.27 | -16.77 | -27.4 | -26.4 | -23.9 | - | - |
| Operating Margin | -59.84% | -31.93% | -28.86% | -17.85% | -20.06% | -13.5% | -18.65% | -28.28% | -11.5% | -5.58% | -8.95% | -8.74% | -7.66% | - | - |
| Earnings before Tax (EBT) 1 | -118.6 | -69 | -67.8 | -42.21 | -53.72 | -38.28 | -52.02 | -77.97 | -38.32 | -20.73 | -30 | -30 | -28 | - | - |
| Net income 1 | -144.8 | -62.33 | -68.73 | -37.85 | -46.66 | -34.24 | -45.48 | -61.58 | -44.96 | -21.1 | -29.15 | -28.2 | -25.85 | - | - |
| Net margin | -76.16% | -30.69% | -32.8% | -17.4% | -20.34% | -13.56% | -17.52% | -23.42% | -16.02% | -7.02% | -9.53% | -9.33% | -8.29% | - | - |
| EPS 2 | -0.3200 | -0.1800 | -0.1900 | -0.1100 | -0.1300 | -0.0900 | -0.1300 | -0.1700 | -0.1200 | -0.0600 | -0.0614 | -0.0656 | -0.0640 | -0.0550 | -0.0468 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/22 | 5/9/22 | 8/9/22 | 11/8/22 | 3/8/23 | 5/10/23 | 8/9/23 | 11/8/23 | 2/28/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 23.5 | 116 | 201 | 137 | 114 | - |
| Net Cash position 1 | - | - | - | - | - | - | 7.07 |
| Leverage (Debt/EBITDA) | - | 0.4783 x | 2.211 x | 3.412 x | 1.526 x | 0.9341 x | - |
| Free Cash Flow 1 | - | -85.1 | -26.5 | -57.4 | 10.6 | 39 | 57 |
| ROE (net income / shareholders' equity) | - | -27.1% | -14.1% | -12.6% | -6.48% | -5.03% | -3.32% |
| ROA (Net income/ Total Assets) | - | -19.7% | -10.5% | -8.7% | -5.07% | -3.9% | -3.18% |
| Assets 1 | - | 1,748 | 2,050 | 2,142 | 1,773 | 1,960 | 1,511 |
| Book Value Per Share 2 | - | 4.130 | 4.040 | 3.770 | 3.650 | 3.620 | 3.630 |
| Cash Flow per Share 2 | - | 0.0300 | 0.1500 | -0.0500 | 0.1100 | 0.2400 | - |
| Capex 1 | - | 94.5 | 79.3 | 40.5 | 32.6 | 57.3 | 68.7 |
| Capex / Sales | - | 14.16% | 9.22% | 3.84% | 2.67% | 4.16% | 4.41% |
| Announcement Date | 4/12/21 | 3/10/22 | 3/8/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
6.86
USD
Average target price
8.786
USD
Spread / Average Target
+28.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.39% | 2.62B | |
| +20.68% | 85.55B | |
| -29.31% | 70.07B | |
| +9.23% | 29.06B | |
| -8.63% | 17.51B | |
| +2.14% | 17.39B | |
| +0.39% | 15.38B | |
| +6.47% | 13.4B | |
| +68.09% | 12.87B | |
| +6.43% | 12.77B |
- Stock Market
- Equities
- LFST Stock
- Financials LifeStance Health Group, Inc.